Table 1.

Patient characteristics

Variable	n (%)
Age (years), median (range)	67.1 (50.6–90.7)
Radical radiotherapy
No	26 (63.4)
Yes	15 (36.6)
Prostatectomy
No	27 (65.9)
Yes	14 (34.1)
Histology
CRPC-Adeno	21 (51.2)
CRPC-NE	20 (48.8)
Presence of metastases at diagnosis
No	19 (46.3)
Yes	22 (53.7)
Bone metastases
No	8 (19.5)
Yes	33 (80.5)
Lymph node metastases
No	18 (43.9)
Yes	23 (56.1)
Visceral metastases
No	19 (46.3)
Yes	22 (56.1)
Type of platinum chemotherapy
Combination therapy	38 (92.7)
Monotherapy	3 (7.3)
Number of prior systemic therapies, median (range)	2 (1–7)
Prior AR-directed therapies
No	18 (43.9)
Yes	23 (56.1)
Presence of pain/opiates use at baseline
No	30 (73.7)
Yes	11 (24.3)
Baseline PSA, ng/mL median (range)	10.5 (0.89–1500)
Baseline serum CGA before platinum therapy, ng/mL
CGA < 95	19 (46.3)
CGA ≥ 95	22 (56.1)
Baseline serum LDH before platinum therapy, U/L
LDH <192	14 (34.1)
LDH ≥192	27 (65.9)
Whole exome data available
No	9 (22.0)
Yes	32 (78.0)
AR alterations
No	19 (59.4)
Yes	13 (40.6)
TP53 alterations
No	16 (50)
Yes	16 (50)
RB1 alterations
No	17 (53.1)
Yes	15 (46.9)
PTEN alterations
No	17 (53.1
Yes	15 (46.9)
DNA defect repair * alterations
No	21 (79.7%)
Yes	11 (34.3%)

^*DNA repair alterations included BRCA1 and BRCA2 mutation or deletion, and ATM mutation.

Abbreviations. AR, androgen receptor; ATM, ataxia telangiectasia mutated gene; BRCA, breast cancer gene; CGA, chromogranin A; CRPC-Adeno, castration-resistant prostate adenocarcinoma; CRPC-NE, castration-resistant prostate cancer with neuroendocrine features; LDH, lactate dehydrogenase; n, number; PSA, prostate specific antigen; PTEN, phosphatase and tensin homolog; RB1, retinoblastoma 1; TP53, tumor protein p53.